THIRTY YEARS OF COLLABORATION HAS LED TO THE CREATION OF KATEXCO PHARMACEUTICALS CORP

Katexco Pharmaceuticals Corp is a Medical Marijuana company with novel treatments that were created from ground breaking research at Stanford University, by its Executive Chairman of the Board, Prof Lawrence Steinman and its CEO, Dr Jonathan Rothbard. Prof Steinman and Dr Rothbard joined forces with Prof Sir Marc Feldmann, an Oxford Professor, who discovered a whole class of drugs for treatment of rheumatoid arthritis and inflammatory bowel disease.

The Katexco team identified a key receptor for the amyloid proteins associated with diseases like Alzheimer’s and Parkinson’s Disease. The receptor is called alpha 7 nicotinic acetylcholine receptor (nA7AChR) and shares an important biochemical signalling pathway within immune cells that CBD, the critical ingredient in Marijuana and purified derivatives of this plant. This receptor-nA7AChR- is found on key cells of the immune system. Prof Steinman and Dr Rothbard showed that small molecules available as drugs taken by mouth can engage this receptor on immune cells and then potently reduce inflammatory diseases.

Thus, Katexco’s technology can amplify and optimize the synergistic effects of orally available combinations of cannabinoids and nA7ACHR agonists, when given in a prescribed regimen. Katexco plans to develop molecules that engage nA7ACHR and thereby activate common aspects of these two key anti-inflammatory receptor systems-α7NAChR and CB-R for treatment of various disease.

Katexco is pursuing research based on studies conducted by the founders at Stanford University, for which it already has worldwide exclusive licensed patents.